67
Views
4
CrossRef citations to date
0
Altmetric
Review

The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice

&
Pages 587-593 | Published online: 10 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

KR Jyothi, Jagadish Beloor, Ara Jo, Minh Nam Nguyen, Tae Gyu Choi, Jin-Hwan Kim, Salima Akter, Sang-Kyung Lee, Chi Hoon Maeng, Hyung Hwan Baik, Insug Kang, Joohun Ha & Sung Soo Kim. (2015) Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication. International Journal of Nanomedicine 10, pages 903-921.
Read now

Articles from other publishers (3)

Kaniz Afroz Tanni & Jingjing Qian. (2023) Comparative safety of generic versus brand calcineurin inhibitors in solid organ transplant patients: A systematic review and meta-analysis. Journal of the American Pharmacists Association 63:3, pages 709-719.
Crossref
Jie Liu, Yue Wang, Qiwei Zhuang, Meng Chen, Yufeng Wang, Lina Hou & Fei Han. (2016) Protective effects of cyclosporine A and hypothermia on neuronal mitochondria in a rat asphyxial cardiac arrest model. The American Journal of Emergency Medicine 34:6, pages 1080-1085.
Crossref
Angel Rubín & Marina Berenguer. 2016. Disease Recurrence After Liver Transplantation. Disease Recurrence After Liver Transplantation 35 54 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.